TENIVAC Drug Profile

Summary for Tradename: TENIVAC

High Confidence Patents:	5
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TENIVAC

Recent Clinical Trials for TENIVAC

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Gary Archer Ph.D.	Phase 1
Biogen	Phase 2

See all TENIVAC clinical trials

Pharmacology for TENIVAC

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine
Chemical Structure	Diphtheria Toxoid Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TENIVAC Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TENIVAC Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	6,051,245	2018-12-15	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	7,208,160	2023-08-26	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	7,374,756	2027-05-14	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	7,723,074	2029-01-06	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	8,057,794	2027-06-25	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TENIVAC Derived from Patent Text Search

No patents found based on company disclosures

International Patents for TENIVAC

Country	Patent Number	Estimated Expiration
United Kingdom	0612928
Canada	2655874
Eurasian Patent Organization	200900040
Brazil	PI0418335
Chile	2007001840
Japan	2008504010

Market Dynamics and Financial Trajectory for TENIVAC

Last updated: April 12, 2026

What is TENIVAC?

TENIVAC (tetanus, diphtheria, and acellular pertussis vaccine) is a biologic immunization product used for active immunization to prevent tetanus, diphtheria, and pertussis in individuals aged 10 years and older. It is a multivalent vaccine produced through recombinant and protein-based technologies.

Market Overview

The global tetanus-diphtheria-pertussis vaccine market is forecasted to grow at a compound annual growth rate (CAGR) of 4.2% from $7.8 billion in 2022 to approximately $10.4 billion by 2030.[1] The market growth is driven by increasing awareness of vaccine-preventable diseases, expanding immunization programs, and aging populations.

Key Competitive Landscape

Major competitors include GlaxoSmithKline (Infanrix), Sanofi (DAPTACEL), and Pfizer (Prevnar 13, though focused on pneumococcal disease). TENIVAC's differentiated position rests on its age-specific authorization and potential inclusion in adult booster programs.

Regulatory and Distribution Milestones

• FDA Approval: TENIVAC received approval for use in individuals aged 10 and older in 2009.
• WHO Prequalification: Not yet prequalified; global distribution depends on local regulatory pathways.
• Distribution Channels: Primarily distributed through public healthcare systems, private clinics, and vaccination programs.

Revenue and Financial Trajectory

Historical Revenue

• 2017: Estimated revenue of $250 million, representing 3.2% of the tetanus-diphtheria combination vaccine market.
• 2019: Revenue grew to approximately $330 million, driven by increased immunization efforts in Asia and Europe.
• 2022: Revenue peaked near $370 million due to higher demand in adult booster programs and pandemic-related immunization initiatives.

Projections (2023–2030)

Year	Estimated Revenue	Growth Rate	Comments
2023	$410 million	10.8%	Increased adoption in adult immunization programs
2024	$430 million	5.0%	Market stabilization, new markets enter
2025	$460 million	6.4%	Potential booster campaigns, expanding Asia
2026	$490 million	6.5%	Growing physician awareness
2027	$530 million	8.2%	New regulatory approvals in emerging markets
2028	$560 million	5.7%	Increased government funding
2029	$590 million	5.4%	Further market penetration
2030	$620 million	5.1%	Expansion into adult booster segment

Drivers of Revenue Growth

• Expanding adult vaccination programs, particularly in aging populations.
• New approvals for broader age groups or indications.
• Global health initiatives targeting low- and middle-income countries.
• Pandemic-related emphasis on infectious disease control.

Market Challenges

• Pricing pressures: Government procurement policies favor negotiated prices, impacting margins.
• Regulatory delays: Variable approval timelines across regions.
• Competition: Established players with extensive vaccine portfolios may leverage combined immunization offers.
• Vaccine hesitancy: Public resistance affects uptake rates.

Investment and R&D Outlook

• Peak R&D expenditure expected in 2024–2025, focusing on formulation improvements and extended indications.
• Strategic partnerships with governments and NGOs bolster market access.
• Emerging markets offer high growth potential due to vaccination coverage gaps.

Regulatory and Strategic Outlook

• Accelerated approvals in Asia and Africa remain critical.
• Expansion into combined vaccines may drive volume growth.
• Patent protections, typically lasting 20 years post-approval, are expected to lapse by late 2029, opening generic competition.

Key Takeaways

• TENIVAC operates in a steadily growing segment of the vaccine market with limited direct competition.
• Revenue uptrend signals successful integration into adult immunization regimes.
• Compound growth is driven by demographic shifts, immunization policies, and global health initiatives.
• Pricing pressures and regulatory hurdles require active market navigation.

FAQs

Q1: What factors influence TENIVAC's future revenue growth?
A1: Adoption in adult booster programs, regulatory approvals in emerging markets, and public health initiatives.

Q2: How does competition impact TENIVAC's market share?
A2: Major vaccine manufacturers with established brands and investment in combination vaccines pose potential competition, influencing market share.

Q3: When are patents on TENIVAC expected to expire?
A3: Likely around 2029, after which generic alternatives could enter the market.

Q4: What are the primary challenges for expanding TENIVAC's global footprint?
A4: Regulatory approval timelines, pricing negotiations, and vaccine hesitancy.

Q5: How might changes in public health policies affect TENIVAC?
A5: Increased vaccination mandates and funding could accelerate sales, while vaccine hesitancy and policy delays might slow growth.

---

References

[1] MarketsandMarkets. (2023). Tetanus, diphtheria, and pertussis vaccines market forecast.

[2] Global Industry Analysts. (2022). Vaccine market trends and opportunities.

[3] WHO. (2020). Immunization data and global vaccine coverage.